Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Prior treatment

• uncontrolled cardiac and other comorbidities within 6 months prior to the first dose
• Major surgery or severe trauma within 4 weeks before the first dose, or planned major surgery during the study
• History of oesophageal varices, severe ulcers, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months prior to the first dose

Other illness

• Clinically significant risk of haemorrhage or fistula
• History of another malignancy within 3 years
• History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• active autoimmune diseases requiring systemic treatment within the past 2 years
• History of severe bleeding tendency or coagulation dysfunction
• Acute, chronic or symptomatic infections
• Participants with history of immunodeficiency

Other

• Participants may be excluded if they meet any of the following:
• Known active brain lesions including leptomeningeal metastasis, brainstem, meningeal or spinal cord metastases or compression.

• 18 years of age or older at screening
• Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC with diagnosis confirmed by histology/cytology
• At least one measurable (as defined by the investigator) and untreated lesion
• Adequate hematologic, hepatic, cardiac and renal function
• No prior systemic therapy for RCC (immunotherapy after surgery is allowed if received \>12 months prior)
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) based risk categories